SL Science Holding Shares Surge 35% on Nasdaq Debut After SPAC Merger as Biotech Investor Interest Builds
SL Science Holding Limited (formerly SL BIO Ltd.) began trading on Nasdaq Global Market under ticker SLBT on June 15 after completing a SPAC merger with Horizon Space Acquisition II Corp. Shares rose ~34% to close at $5.99. The deal valued the combined entity at about $5.6B, funding gamma delta T-cell therapies and other cell/gene and exosome programs.
How this was made
The 30-second read
Why it matters
The article’s actionable element is the quantified debut performance (~34%+ close) tied to the SPAC-to-Nasdaq transition, which can drive short-term momentum trading and heightened volatility.
Market read
Traders can treat this as a fresh, first-day liquidity/momentum event for a newly public biotech, with sentiment supportive for cell-therapy platforms but fundamentals still preclinical.
What to watch
No details are provided on PIPE size/terms, cash on balance sheet, dilution, or near-term clinical milestones—key drivers that can dominate after the initial trading pop.
Background
SL Science Holding (formerly SL BIO Ltd.) completed a business combination with Horizon Space Acquisition II Corp. and began trading on Nasdaq under SLBT on June 15.
Ticker impact
SL Science Holding debuted on Nasdaq via a SPAC merger and shares jumped ~34% to $5.99, signaling fresh trading demand for its cell-therapy platform.
Near-term volatility likely elevated after the debut; follow-through depends on post-listing liquidity and any early clinical/regulatory updates.
This is a primary, same-day market-move catalyst (Nasdaq debut + SPAC completion) with a quantified close and ticker transition, but no new clinical or financial datapoint beyond the listing mechanics.
Market effects
Reinforces investor appetite for off-the-shelf cell therapy and immuno-oncology platforms, potentially supporting sentiment for similar preclinical SPAC-to-Nasdaq biotech stories.
Taiwan-headquartered biotech transitioning to US public markets may draw incremental cross-border biotech capital flows.
Highlights continued global funding interest in cell/gene therapy despite sector manufacturing and clinical-risk headwinds.
Counterpoint
A debut-day surge can fade quickly if the move is driven more by SPAC/listing mechanics and momentum than by new clinical evidence.
Key entities
- companySL Science Holding Limited
Preclinical cell therapy and regenerative medicine company that began trading on Nasdaq as SLBT after a SPAC merger.
- SPACHorizon Space Acquisition II Corp.
Special purpose acquisition company involved in the business combination that enabled SL Science’s Nasdaq listing.
